Continuous glucose monitoring (CGM) shows potential for identifying gestational diabetes but cannot replace the oral glucose tolerance test (OGTT) as the diagnostic standard.
2
CGM metrics, such as mean glucose levels and glycemic variability, can differentiate patients who develop gestational diabetes from those who do not.
3
Higher time above target glucose levels correlates with adverse neonatal outcomes, including larger birth weights and respiratory distress.
4
Randomized trials on CGM for managing gestational diabetes yielded mixed results regarding maternal and neonatal outcomes.
5
Current evidence is insufficient to validate CGM as a standalone diagnostic tool for gestational diabetes, necessitating further research.
